Holen Sie sich die Stockscreener-App
1.79
2.73%
-0.04
Caribou Biosciences Inc Aktie (CRBU) Neueste Nachrichten
The Gross Law Firm Notifies Shareholders of Caribou Biosciences, - GuruFocus
Caribou Biosciences stock holds focus on CRISPR therapies - AD HOC NEWS
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Index - marketscreener.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Investing News Network
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Microcap Value Benchmark Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Value Benchmark - marketscreener.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire Inc.
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell Microcap Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Small Cap Completeness Index - marketscreener.com
CRBUCaribou Biosciences Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences - The National Law Review
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Dynamic Index - marketscreener.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirt - The National Law Review
Caribou Biosciences Inc (CRBU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Caribou Biosciences, Inc. Actuals & Estimates (NASDAQ:CRBU) - TradingView
CRBU Forecast — Price Target — Prediction for 2027 - TradingView
Caribou Biosciences Inc (CRBU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Caribou Biosciences StockLong-term CRISPR strategy in focus - AD HOC NEWS
Caribou Biosciences Shareholders Decide Key Governance Matters - TipRanks
Caribou Biosciences (NASDAQ: CRBU) holders reject officer exculpation - Stock Titan
Caribou Biosciences Inc (CRBU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Caribou Biosciences Inc (CRBU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Caribou Biosciences Inc (CRBU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CRBU Q1 2026 Earnings: EPS Beat Offers Little Reprieve as Stock SlipsTech Earnings Analysis - newsline.com
Caribou Biosciences Inc (CRBU) Institutional Confidence - TradingKey
Caribou Biosciences Inc (CRBU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Caribou Biosciences Inc (CRBU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Caribou Biosciences Inc (CRBU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy - Investing.com
Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses - CRISPR Medicine News
Investors who lost money on Caribou Biosciences, Inc.(CRBU) shou - GuruFocus
Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026 - Traders Union
Caribou Biosciences (CRBU) Slides 3.92%, Nears Critical Support at $1.51Catalyst Driven Stocks - newsline.com
Caribou Biosciences, Inc. (CRBU) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA - Traders Union
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 - Investing News Network
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association Annual Meeting - Investing News Network
Caribou reports phase 1 trial data for off-the-shelf CAR-T therapy - Investing.com UK
Caribou Biosciences Reports Long-Term Vispa-Cel Data in Second-Line Large B Cell Lymphoma - marketscreener.com
Caribou reports phase 1 data for off-the-shelf CAR-T therapy - Investing.com UK
Caribou reports phase 1 data for off-the-shelf CAR-T therapy By Investing.com - Investing.com Australia
Caribou Biosciences Highlights Strong Allogeneic CAR-T Trial Results - TipRanks
CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update - Traders Union
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Caribou Biosciences (CRBU) reports durable phase 1 CAR-T responses in lymphoma and myeloma - Stock Titan
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears - Yahoo Finance
Caribou Biosciences (CRBU) Declines 7% as Key Support Level ApproachesVolatility Smirk - newsline.com
Caribou Biosciences advances CRISPR-based CAR-T... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
CRBU: Pivotal-ready and phase I CAR T programs advance, with major data updates expected at EHA - TradingView
CRBU Technical Analysis | Trend, Signals & Chart Patterns | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
CRBU DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 24 Deadline in Securities Class ActionCRBU - TMX Newsfile
Analyst Raises Caribou Biosciences Price Target Following Strong Results - asatunews.co.id
H.C. Wainwright Raises Caribou Biosciences Stock Price Target to $11 - HarianBasis.co
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows - Yahoo Finance
CRBU Q1 2026 Earnings: Narrower-than-expected Loss Drives Shares HigherEarnings Volatility Report - lwvtexas.org
Caribou Biosciences (CRBU) Edges Higher as Stock Tests Key Resistance LevelsEarnings Breakout Stocks - newsline.com
1.16%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):